Guardant Health, Inc. (NASDAQ:GH) Director Stanley J. Meresman sold 4,934 shares of the company’s stock in a transaction dated Monday, January 11th. The stock was sold at an average price of $142.00, for a total transaction of $700,628.00. Following the sale, the director now directly owns 8,993 shares of the company’s stock, valued at approximately $1,277,006. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Guardant Health stock opened at $159.36 on Thursday. The business has a 50 day moving average of $128.69 and a 200-day moving average of $105.13. Guardant Health, Inc. has a 1 year low of $55.90 and a 1 year high of $163.42. The company has a market capitalization of $15.93 billion, a P/E ratio of -83.43 and a beta of 0.58.
Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.44). Guardant Health had a negative net margin of 67.14% and a negative return on equity of 19.22%. The firm had revenue of $74.66 million during the quarter, compared to analyst estimates of $65.99 million. During the same period in the prior year, the company earned ($0.14) EPS. The business’s quarterly revenue was up 22.8% compared to the same quarter last year. As a group, equities research analysts predict that Guardant Health, Inc. will post -2.05 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its holdings in Guardant Health by 3.6% in the third quarter. California State Teachers Retirement System now owns 132,503 shares of the company’s stock valued at $14,811,000 after acquiring an additional 4,633 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Guardant Health by 32.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 254,133 shares of the company’s stock valued at $20,618,000 after acquiring an additional 62,145 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Guardant Health by 121.2% in the third quarter. DekaBank Deutsche Girozentrale now owns 42,250 shares of the company’s stock valued at $4,700,000 after acquiring an additional 23,150 shares during the last quarter. NEXT Financial Group Inc bought a new position in shares of Guardant Health during the 3rd quarter worth approximately $78,000. Finally, Lord Abbett & CO. LLC boosted its holdings in shares of Guardant Health by 4.1% during the 3rd quarter. Lord Abbett & CO. LLC now owns 300,427 shares of the company’s stock worth $33,581,000 after buying an additional 11,811 shares in the last quarter. Institutional investors and hedge funds own 76.15% of the company’s stock.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Further Reading: How to track put option volume
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.